Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Specialised Therapeutics' ZEPZELCA (lurbinectedin) plus atezolizumab approved in Australia and Singapore for extensive-stage small cell lung cancer
Small molecule, cancer, combination therapy, small cell lung cancer, PD-L1 inhibitor, first-line maintenance - Read more

GSK's Blenrep (belantamab mafodotin) receives China NMPA approval for relapsed/refractory multiple myeloma based on Ph3 data
Antibody-drug conjugate, cancer, multiple myeloma, BCMA target, combination therapy - Read more

ClearPoint Neuro receives Health Canada approval for Neuro Navigation System, expanding drug delivery platform globally
Cell and gene therapy, neurological, strategic, operational - Read more

Biogen, TJ Biopharma expand partnership for China rights to felzartamab, $100M upfront, $850M biobucks
Licensing deal, autoimmune, rare disease, antibody, milestone payments, royalties - Read more

Genflow Biosciences, Acuitas Therapeutics collaborate on LNP delivery for SIRT6 mRNA gene therapy, fully funded by Acuitas
Research collaboration, gene therapy, drug delivery, rare disease, mRNA - Read more

Nxera Pharma receives $10M milestone from AbbVie in neurological disease GPCR drug discovery collaboration
Research collaboration, neurological, small molecule, milestone payments, drug discovery, royalties - Read more

LIR Life Sciences, Resilience BioSciences collaborate on preclinical drug research for $5,000 monthly
Research collaboration, drug discovery, small molecule, preclinical research, non-opioid therapeutics - Read more

SynSmart, Amporin Pharmaceuticals collaborate to develop small molecule therapeutics for degenerative diseases
Research collaboration, small molecule, neurological, rare disease, drug discovery - Read more

Struggling with your sales & marketing stack as you’re selling into biotech & life sciences? We’re here to help with a free webinar.

Come learn the importance of brand establishment, proper segmentation of your target ICP, thought leadership content development, omnichannel approaches to outreach campaigns, and personalized, high-touch outreach.

Presented by Hapatune, a boutique marketing firm for bioprocess and life science companies, and Science 2 Sales, a lead-gen and GTM agency helping companies sell into biotech, life sciences, and pharma.

Grab your spot before it’s all filled out!

AstraZeneca's (tozorakimab) meets primary endpoint in Ph3 trial for chronic obstructive pulmonary disease
Antibody, respiratory disease, monoclonal antibody, COPD, IL-33 inhibitor - Read more

Sanofi's Nuvaxovid outperforms Moderna's mNexspike in Ph4 tolerability trial for coronavirus disease 2019
Vaccine, infectious disease, protein subunit vaccine, mRNA vaccine, COVID-19, tolerability - Read more

Nektar Therapeutics' (rezpegaldesleukin) shows extended hair regrowth in Ph2 alopecia areata study at 52 weeks
Protein therapy, autoimmune, interleukin, alopecia areata, eczema - Read more

Kyverna Therapeutics' (mivocabtagene autoleucel) shows durable Ph2 responses in generalised myasthenia gravis at one year
Cell therapy, autoimmune, CAR-T, myasthenia gravis, neuromuscular disease - Read more

Lytix Biopharma's ruxotemitide (LTX-315) shows Ph2 promise in PD-1/PD-L1 refractory advanced melanoma with pembrolizumab combination
Small molecule, cancer, intratumoral therapy, melanoma, PD-1/PD-L1 refractory, combination therapy - Read more

Novo Nordisk's (etavopivat) meets Ph3 primary endpoint, reducing vaso-occlusive crises in sickle cell disease
Small molecule, blood disorder, pyruvate kinase activator, sickle cell disease, gene therapy - Read more

Pulnovo Medical raises $100M, advancing pulmonary hypertension and heart failure interventional therapies
Pulmonary hypertension, cardiovascular, medical device, clinical-stage - Read more

ViewsML raises $4.9M seed funding to accelerate AI-driven virtual biomarker staining platform
AI/ML platform, biomarker discovery, digital pathology, oncology, platform-enabled - Read more

Odyssey Therapeutics files for IPO, targeting autoimmune and inflammatory disease treatments
Autoimmune, small molecule, inflammatory disease, clinical-stage - Read more

Boehringer Ingelheim invests £150M ($202.2M) to open AI drug R&D hub in London over 10 years
AI/machine learning, drug discovery, strategic, major transaction - Read more

Roche acquires SAGA Diagnostics for $595M to bolster Foundation Medicine's MRD diagnostics portfolio
Diagnostics, oncology, strategic, major transaction - Read more

Eli Lilly acquires Kelonia Therapeutics for up to $7B to expand in vivo CAR-T capabilities
CAR-T, oncology, strategic, major transaction - Read more

Trump signs executive order to accelerate psychedelic therapy development, boosting Compass Pathways shares 25%
Psychedelic therapy, mental health, regulatory, financial - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Agenus, MiNK Therapeutics' botensilimab-balstilimab-agenT-797 cocktail records 0% response rate in Ph2 gastroesophageal adenocarcinoma trial
Cell therapy, cancer, antibody, combination therapy, gastroesophageal adenocarcinoma, iNKT cell therapy - Read more

Arcus' domvanalimab (anti-TIGIT) Ph3 trial in non-small-cell lung cancer discontinued for futility
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, TIGIT, PD-1 inhibitor - Read more

Judge rejects Bayer's bid to block J&J's Erleada survival claims over Nubeqa in prostate cancer dispute
Small molecule, oncology, competitive, regulatory - Read more

Bristol Myers Squibb cuts 206 more New Jersey jobs amid ongoing $2B cost-reduction restructuring effort
Operational, cost reduction, financial - Read more

Theramex exits UK pharma self-regulatory body after systemic compliance failures and public reprimand
Small molecule, women's health, regulatory, operational, compliance - Read more

Passage Bio shares plunge 37% after FDA demands randomized trial for FTD gene therapy PBFT02
Gene therapy, neurological, regulatory, strategic, rare disease - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here